Cargando…
Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of L1 and L5 Vertebral Body CT Attenuation
Background: Radiotherapy is a risk factor for osteoporosis and insufficiency fractures via osteoblast apoptosis and vascular injury. PTH analogs teriparatide and abaloparatide are contraindicated in patients with prior exposure to radiotherapy crossing bone due to the increased risk of osteosarcoma....
Autores principales: | Adly, Hussein, Ing, Steven |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8089160/ http://dx.doi.org/10.1210/jendso/bvab048.440 |
Ejemplares similares
-
Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of CT Attenuations at L1 and L5
por: Schneider, Gary K, et al.
Publicado: (2022) -
OR13-05 Romosozumab Treatment Lowers the Incidence of New Vertebral Fractures Across All Fracture Severity Grades Among Postmenopausal Women with Osteoporosis
por: Feldman, Robert, et al.
Publicado: (2020) -
FRI683 Every Dose Counts: Response To Half The Recommended Dose Of Romosozumab
por: Ramchandani, Bhanvi Prakash, et al.
Publicado: (2023) -
RF30 | PSAT138 Romosozumab-aqqg in the Treatment of Osteoporosis in a Patient with Hypophosphatasia
por: Khanjee, Naveed, et al.
Publicado: (2022) -
ODP132 Efficacy of Romosozumab for Osteoporosis in a Patient with Hajdu-Cheney Syndrome: A Case Report
por: Kim, Kyoung Jin, et al.
Publicado: (2022)